source
- FDA pushes back decision on Capricor’s Duchenne cell therapy, GSK clears hepatitis B drug in JapanThe U.S. Food and Drug Administration has extended its review of Capricor Therapeutics' experimental Duchenne muscular dystrophy cell therapy, deramiocel. The agency moved its decision deadline fro…
- Qiagen appoints new chief executive after 9-month searchMolecular diagnostics specialist Qiagen has a new CEO as Jonathan M. Pratt takes the reins.Fierce Biotech · 10h ago↗ source